This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Lundbeck Seattle BioPharmaceuticals, Inc.
Lundbeck Seattle BioPharmaceuticals, Inc., a subsidiary of the global pharmaceutical company Lundbeck, is headquartered in the United States, with significant operations in the Seattle region. Founded in 2018, the company focuses on developing innovative treatments for central nervous system disorders, including depression and schizophrenia. Lundbeck Seattle BioPharmaceuticals is renowned for its commitment to advancing neuroscience, leveraging cutting-edge research to create unique therapies that address unmet medical needs. The company’s core products are designed to improve patient outcomes and enhance quality of life, setting it apart in a competitive market. With a strong emphasis on scientific excellence, Lundbeck Seattle BioPharmaceuticals has quickly established itself as a key player in the biopharmaceutical industry, contributing to Lundbeck's legacy of innovation and patient care.
DitchCarbon Score
How does Lundbeck Seattle BioPharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lundbeck Seattle BioPharmaceuticals, Inc.'s score of 83 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Lundbeck Seattle BioPharmaceuticals, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of H. Lundbeck A/S, which cascades its climate commitments and initiatives down to its subsidiaries. While specific emissions data is not available, Lundbeck Seattle BioPharmaceuticals aligns with the sustainability goals set by its parent company, H. Lundbeck A/S. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the corporate level by H. Lundbeck A/S. These initiatives aim to establish science-based targets for reducing greenhouse gas emissions across their operations. As a subsidiary, Lundbeck Seattle BioPharmaceuticals is expected to adhere to the climate strategies and reduction targets set by H. Lundbeck A/S, although specific targets for Lundbeck Seattle BioPharmaceuticals have not been detailed. The overarching commitment to sustainability reflects a broader industry trend towards reducing carbon footprints and enhancing environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 6,626,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 13,317,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lundbeck Seattle BioPharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
